Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

NCT ID: NCT04819776

Last Updated: 2024-04-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

417 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-22

Study Completion Date

2023-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar I Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iloperidone

Group Type EXPERIMENTAL

Iloperidone

Intervention Type DRUG

Oral iloperidone

Placebo

Group Type PLACEBO_COMPARATOR

Iloperidone Placebo

Intervention Type DRUG

Oral placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iloperidone

Oral iloperidone

Intervention Type DRUG

Iloperidone Placebo

Oral placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FANAPTĀ® VYV-683

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients 18 to 65 years of age (inclusive)
* Diagnosed with bipolar I disorder, manic or mixed-type, per DSM-5 criteria
* Voluntary hospitalization for current manic episode

Exclusion Criteria

* Patients with a DSM-5 diagnosis of a psychiatric disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months
* Patients who are experiencing a first manic episode or meeting criteria for rapid cycling
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vanda Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vanda Investigational Site

Little Rock, Arkansas, United States

Site Status

Vanda Investigational Site

Rogers, Arkansas, United States

Site Status

Vanda Investigational Site

Cerritos, California, United States

Site Status

Vanda Investigational Site

Culver City, California, United States

Site Status

Vanda Investigational Site

Long Beach, California, United States

Site Status

Vanda Investigational Site

Orange, California, United States

Site Status

Vanda Investigational Site

Torrance, California, United States

Site Status

Vanda Investigational Site

Miami Lakes, Florida, United States

Site Status

Vanda Investigational Site

Oakland Park, Florida, United States

Site Status

Vanda Investigational Site

Atlanta, Georgia, United States

Site Status

Vanda Investigational Site

Decatur, Georgia, United States

Site Status

Vanda Investigational Site

Gaithersburg, Maryland, United States

Site Status

Vanda Investigational Site

Flowood, Mississippi, United States

Site Status

Vanda Investigational Site

Las Vegas, Nevada, United States

Site Status

Vanda Investigational Site

Marlton, New Jersey, United States

Site Status

Vanda Investigational Site

Dayton, Ohio, United States

Site Status

Vanda Investigational Site

North Canton, Ohio, United States

Site Status

Vanda Investigational Site

Austin, Texas, United States

Site Status

Vanda Investigational Site

DeSoto, Texas, United States

Site Status

Vanda Investigational Site

Richardson, Texas, United States

Site Status

Vanda Investigational Site

Novi Iskar, Sofia-Grad, Bulgaria

Site Status

Vanda Investigational Site

Tserova Koria, Veliko Tarnovo, Bulgaria

Site Status

Vanda Investigational Site

Kardzhali, , Bulgaria

Site Status

Vanda Investigational Site

Lovech, , Bulgaria

Site Status

Vanda Investigational Site

Veliko Tarnovo, , Bulgaria

Site Status

Vanda Investigational Site

Vratsa, , Bulgaria

Site Status

Vanda Investigational Site

Tuszyn, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Poland

References

Explore related publications, articles, or registry entries linked to this study.

Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024 Jan 15;85(1):23m14966. doi: 10.4088/JCP.23m14966.

Reference Type DERIVED
PMID: 38236020 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VP-VYV-683-3201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.